These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 6751062)

  • 1. MAC study confirms pharmacy losses.
    Torielli G; Gagnon JP; Lingle EW
    Am Pharm; 1982 Aug; NS22(8):31-3. PubMed ID: 6751062
    [No Abstract]   [Full Text] [Related]  

  • 2. Will HCFA jump NHI on outpatient drug coverage?
    Eastman M
    Am Pharm; 1978 Aug; 18(9):43. PubMed ID: 354364
    [No Abstract]   [Full Text] [Related]  

  • 3. [The selective financing of drugs].
    Ortún Rubio V
    Rev Enferm; 1990; 13(143-4):13-5. PubMed ID: 2396063
    [No Abstract]   [Full Text] [Related]  

  • 4. The MAC concept: a historical perspective.
    Francis WR; Gammill CG; Braucher CL
    Med Mark Media; 1980 Sep; 15(9):56-68. PubMed ID: 10297991
    [No Abstract]   [Full Text] [Related]  

  • 5. Controlling pharmacy costs in the NC Medicaid program.
    Dobson LA
    N C Med J; 2003; 64(6):280-2. PubMed ID: 14983617
    [No Abstract]   [Full Text] [Related]  

  • 6. Adverse selection in private, stand-alone drug plans and techniques to reduce it.
    Boccuti C; Moon M
    Policy Brief Commonw Fund; 2003 Oct; (681):1-9. PubMed ID: 14562798
    [No Abstract]   [Full Text] [Related]  

  • 7. Outpatient drugs: Medicare's new benefit.
    Grimaldi PL
    Nurs Manage; 1988 Sep; 19(9):15-7. PubMed ID: 3050642
    [No Abstract]   [Full Text] [Related]  

  • 8. Health Care Financing Administration: Pharmaceutical Reimbursement Board; final maximum allowable cost determinations.
    Fed Regist; 1979 Aug; 44(169):50651-6. PubMed ID: 10297564
    [No Abstract]   [Full Text] [Related]  

  • 9. Medicaid reimbursement.
    Berry MD
    Issue Brief Health Policy Track Serv; 2008 Jan; ():1-31. PubMed ID: 18345577
    [No Abstract]   [Full Text] [Related]  

  • 10. Using clinical evidence to manage pharmacy benefits: experiences of six states.
    Bergman D; Hoadley J; Kaye N; Crowley J; Hostetter M
    Issue Brief (Commonw Fund); 2006 Mar; (899):1-14. PubMed ID: 16562357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. States negligent in addressing long-term financing needs of Medicaid, SCHIP.
    Med Health; 2005 Aug; 59(30):2. PubMed ID: 16173319
    [No Abstract]   [Full Text] [Related]  

  • 12. New federal guidelines: a green light from government.
    Gosselin RA
    Hosp Formul; 1978 Jul; 13(7):546-9. PubMed ID: 10308293
    [No Abstract]   [Full Text] [Related]  

  • 13. Design of a pharmacy benefit of low-income seniors: lessons from state pharmacy assistance programs.
    AcademyHealth, Health Care Financing & Organization
    Find Brief; 2007 Jan; 10(1):1-4. PubMed ID: 17302010
    [No Abstract]   [Full Text] [Related]  

  • 14. State Medicaid prescription drug expenditures for Medicare-Medicaid dual eligibles: estimates of Medicaid savings and federal expenditures resulting from expanded Medicare prescription coverage.
    Dale SB; Verdier JM
    Issue Brief (Commonw Fund); 2003 Apr; (627):1-12. PubMed ID: 12685428
    [No Abstract]   [Full Text] [Related]  

  • 15. The Medicaid gap: lost professional income and increased processing costs.
    Siecker BR
    Am Pharm; 1983 Aug; NS23(8):44-8. PubMed ID: 6353895
    [No Abstract]   [Full Text] [Related]  

  • 16. Potential impact of prepayment on Medicaid drug costs.
    Yesalls CE; Norwood GJ; Lipson DP
    Contemp Pharm Pract; 1979; 2(2):87-94. PubMed ID: 10297462
    [No Abstract]   [Full Text] [Related]  

  • 17. Patient assistance programs: information is not our enemy.
    Choudhry NK; Lee JL; Agnew-Blais J; Corcoran C; Shrank WH
    Health Aff (Millwood); 2009; 28(3):843-4. PubMed ID: 19414896
    [No Abstract]   [Full Text] [Related]  

  • 18. Medicaid: focusing on state innovation.
    Cubanski J; Kline J
    Issue Brief (Commonw Fund); 2003 Apr; (617):1-8. PubMed ID: 12693393
    [No Abstract]   [Full Text] [Related]  

  • 19. Medicaid patients' access to new drugs.
    Grabowski H
    Health Aff (Millwood); 1988; 7(5):102-14. PubMed ID: 3068107
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmaceutical Reimbursement Board; final maximum allowable cost (MAC) determinations for certain drug products--Health Care Financing Administration. Final notice.
    Fed Regist; 1982 Dec; 47(251):58370-2. PubMed ID: 10259800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.